Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are both hematopoietic stem cell disorders. However, while leukemic stem cells have been revealed by clonal tracking experiments, dysplastic stem cells have never been demonstrated by xeno-transplantation assays because of poor engraftment problems. These engraftment difficulties may be due to the unique nature of MDS genetic lesions that are truly able to recapitulate the disease phenotype. MDS and AML of younger patients harbour clonal yet different chromosomal markers, whereas MDS and AML of the elderly present similar defects. Potential involvement of tumor suppressor genes in MDS has been hypothesized but never confirmed, while cooperation between class I and class II mutations has been identified in AML. The reciprocal interactions between stromal cells and neoplastic clones are disrupted in both MDS and AML. In early MDS, stromal and neoplastic cells produce high levels of inhibitory cytokines, whereas in advanced MDS and AML they produce high levels of anti-apoptotic molecules.
Division of Haematology, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy. p.bernasconi@smatteo.pv.it
Paolo
P
Bernasconi
D000328:Adult; D000818:Animals; D017209:Apoptosis / Q000235:genetics; D001853:Bone Marrow / Q000378:metabolism; D002999:Clone Cells / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D051379:Mice; D009154:Mutation; D009190:Myelodysplastic Syndromes / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D013234:Stem Cells / Q000378:metabolism; D017154:Stromal Cells / Q000378:metabolism
D016207:Cytokines